Abstract | OBJECTIVE: METHODS: We enrolled 176 patients treated with maintenance HD therapy and performed a longitudinal observational cohort study for three years. We divided the patients into two groups based on whether or not the received EPA treatment [EPA(+) and EPA(-), respectively]. The primary end-point was all-cause death. We also matched the two groups using propensity score matching and examined the effect of EPA. RESULTS: Before matching, the all-cause mortality rates were 24.0% in the EPA(+) and 11.8% in the EPA(-) groups, which were significantly different (p=0.044). After propensity score matching, the EPA(+) group still showed a significantly better prognosis than the EPA(-) group (p=0.038). A multivariate analysis showed that EPA treatment significantly reduced the risk of all-cause mortality both before and after propensity score matching. CONCLUSION: EPA treatment is independently associated with lower mortality in HD patients.
|
Authors | Tomoko Inoue, Kazuhiro Okano, Yuki Tsuruta, Yukio Tsuruta, Ken Tsuchiya, Takashi Akiba, Kosaku Nitta |
Journal | Internal medicine (Tokyo, Japan)
(Intern Med)
Vol. 54
Issue 24
Pg. 3133-7
( 2015)
ISSN: 1349-7235 [Electronic] Japan |
PMID | 26666599
(Publication Type: Journal Article, Observational Study)
|
Chemical References |
|
Topics |
- Atherosclerosis
(mortality, physiopathology)
- Cause of Death
- Eicosapentaenoic Acid
(administration & dosage)
- Female
- Humans
- Kidney Failure, Chronic
(mortality, physiopathology, therapy)
- Longitudinal Studies
- Male
- Middle Aged
- Prognosis
- Renal Dialysis
(adverse effects)
- Risk
|